Chronic lithium and sodium valproate both decrease the concentration of myoinositol and increase the concentration of inositol monophosphates in rat brain

European Neuropsychopharmacology

Volumn 13, Issue 3, 2003, Pages 199-207

  O'Donnell, T ^a   Rotzinger, S ^a   Nakashima, T T ^b   Hanstock, C C ^b   Ulrich, M ^a   Silverstone, P H ^a  

^a UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Creatine; Inositol monophosphates; Lithium; Myoinositol; N Acetylaspartate; Sodium valproate

Indexed keywords

INOSITOL; INOSITOL PHOSPHATE; LITHIUM; SODIUM CHLORIDE; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIPOLAR DISORDER; BRAIN; BRAIN LEVEL; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; LONG TERM EXPOSURE; MALE; MOOD; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; RAT;

EID: 0037407057     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(03)00011-7     Document Type: Article

References (51)

1. Allison J.H., Stewart M.A. Reduced brain inositol in lithium-treated rats. Nature (New Biol.). 233:1971;267-268.
2. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition:1994;American Psychiatric Association, Washington, DC.
3. 1H spectrum of rat brain by two-dimensional shift correlated and J-resolved NMR spectroscopy. Mag. Reson. Med. 17:1991;285-303.
4. Berridge M.J., Downes C.P., Hanley M.R. Lithium amplifies agonist-dependent phosphatidylinositol responses in brain and salivary glands. Biochem. J. 206:1982;587-595.
5. 1H-NMR spectroscopic studies of brain. Neurosci. Biobehav. Rev. 13:1989;23-31.
6. Bligh E.G., Dyer W.J. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37:1959;911-917.
7. Chen G., Huang L.D., Jiang Y.M., Manji H.K. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J. Neurochem. 72:1999;879-882.
8. Chen G., Manji H.K., Hawver D.B., Wright C.B., Potter W.Z. Chronic sodium valproate selectively decreases protein kinase C α and ε in vitro. J. Neurochem. 63:1994;2361-2364.
9. Chen G., Yuan P., Hawver D.B., Potter W.Z., Manji H.K. Increase in AP-1 transcription factor DNA binding activity by valproic acid. Neuropsychopharmacology. 16:1997;238-245.
10. Deicken R.F., Fein G., Weiner M.W. Abnormal frontal lobe phosphorus metabolism in bipolar disorder. Am. J. Psychiatry. 152:1995;915-918.
11. Deicken R.F., Weiner M.W., Fein G. Decreased temporal lobe phosphomonoesters in bipolar disorder. J. Affect. Disord. 33:1995;198-199.
12. Dixon J.F., Hokin L.E. The antibipolar drug valproate mimics lithium in stimulating glutamate release and inositol 1,4,5-trisphosphate accumulation in brain cortex slices but not accumulation of inositol monophosphates and bisphosphates. Proc. Natl. Acad. Sci. 94:1997;4757-4760.
13. 1H magnetic resonance spectroscopic imaging. J. Cereb. Blood Flow Metab. 14:1994;373-382.
14. Ghoshdastidar D., Dutta R.N., Poddar M.K. In vivo distribution of lithium in plasma and brain. Ind. J. Exp. Biol. 27:1989;950-954.
15. Godfrey P.P., McCkye S.J., White A.M., Wood A.J., Grahame-Smith D.G. Subacute and chronic in vivo lithium treatment inhibits agonist and fluoride -stimulated inositol phosphate production in rat cortex. J. Neurochem. 52:1989;498-506.
16. 31P-NMR on developing dog brain. FEBS. Lett. 178:1984;137-142.
17. Hallcher L.M., Shermann W.R. The effects of lithium ion and other agents on the activity of myoinositol-1-phosphatase from bovine brain. J. Biol. Chem. 255:1980;10896-10901.
18. Hirvonen M.R. Cerebral lithium, inositol and inositol monophosphates. Pharmacol. Toxicol. 69:1991;22-27.
19. Hirvonen M.R., Lihtamo H., Savolainen K. A gas chromatographic method for the determination of inositol monophosphates in rat brain. Neurochem. Res. 13:1988;957-962.
20. Jope R.S., Miller J.M., Ferraro T.N., Hare T.A. Chronic lithium treatment and status epilepticus induced by lithium and pilocarpine cause selective changes of amino acid concentrations in rat brain regions. Neurochem. Res. 14:1989;829-834.
21. 31P MRS. J. Affect. Disord. 22:1991;185-190.
22. Kato T., Takahashi S., Shioiri T., Inubushi T. Brain phosphorus metabolism in depressive disorders detected by phosphorus-31 magnetic resonance spectroscopy. J. Affect. Disord. 26:1992;223-230.
23. 7Li magnetic resonance spectroscopy. J. Affect. Disord. 27:1993;53-59.
24. Kato T., Takahashi S., Shioiri T., Murashita J., Hamakawa H., Inubushi T. Reduction of brain phosphocreatine in bipolar II disorder detected by phosphorus-31 magnetic resonance spectroscopy. J. Affect. Disord. 31:1994;125-133.
25. Lenox R.H., Watson D.G., Patel J., Ellis J. Chronic lithium administration alters a prominent PKC substrate in rat hippocampus. Brain Res. 570:1992;333-340.
26. Li R., Wing L.L., Wyatt R.J., Kirch D.G. Effects of haloperidol, lithium, and valproate on phosphoinositide turnover in rat brain. Pharmacol. Biochem. Behav. 46:1993;323-329.
27. Löscher W., Hörstermann D. Differential effects of vigabatrin, γ-acetylenic GABA, aminooxyacetic acid, and valproate on levels of various amino acids on rat brain regions and plasma. Naunyn-Schmiedeberg's Arch. Pharm. 349:1994;270-280.
28. Lubrich B., Patishi Y., Kofman O., Agam G., Berger M., Belmaker R.H., van Calker D. Lithium-induced inositol depletion in rat brain after chronic treatment is restricted to the hypothalamus. Mol. Psychiatry. 2:1997;407-412.
29. Manji H.K., Lenox R.H. Long-term action of lithium: a role for transcriptional and post-transcriptional factors regulated by protein kinase C. Synapse. 16:1994;11-28.
30. Manji H.K., Potter W.Z., Lenox R.H. Signal transduction pathways. Molecular targets for lithium's actions. Arch. Gen. Psychiatry. 52:1995;531-543.
31. Manji H.K., Chen G., Hsiao J.K., Risby E.D., Masana M.I., Potter W.Z. Regulation of signal transduction pathways by mood-stabilizing agents: implications for the delayed onset of therapeutic efficacy. J. Clin. Psychiatry. 57:(Suppl. 13):1996;34-46.
32. Manji H.K., Bebchuk J.M., Moore G.J., Glitz D., Hasanat K.A., Chen G. Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications. J. Clin. Psychiatry. 60:(Suppl. 2):1999;27-39.
33. Martin-Gallard A., Rodriguez P., Lopet M., Benavides J., Ugarte M. Effects of dipropylacetate on the glycine clearance enzyme system and glycine levels. Biochem. Pharm. 34:1985;2877-2882.
34. Moore G.J., Bebchuk J.M., Manji H.K. Quantitative proton MRS in bipolar affective disorder: monitoring of lithium induced modulation of brain myoinositol. Int. Soc. Magn. Res. Med. 5th Annual Meeting, Vancouver, BC:1997;. Abstract 1214.
35. Moore G.J., Bebchuk J.M., Faulk M.W., Wilds I.B., Seraji-Bozorgzad N., Arfken C.L., Strahl-Bevacqua J., Hasanat K., Jolkovsky L., Manji H.K. Lithium and bipolar disorder: CNS neurochemical changes associated with mood stabilization [abstract. Int. Soc. Magn. Res. Med. 7th annual meeting, Philadelphia, PA:1999;. Abstract 1409.
36. Nahorski S.R., Ragan C.I., Challiss R.A.J. Lithium and the phosphoinositide cycle: an example of uncompetitive inhibition and its pharmacological consequences. Trends Pharmacol. Sci. 12:1991;297-303.
37. Nakano M., Ueda H., Li J.Y., Matsumoto M., Yanagihara T. Measurement of regional N-acetylaspartate after transient global ischemia in gerbils with or without ischemic tolerance: an index of neuronal survival. Ann. Neurol. 44:1998;334-340.
38. Ozaki N., Chuang D.-M. Lithium increases transcription factor binding to AP-1 and cyclic AMP-responsive element in cultured neurons and rat brain. J. Neurochem. 69:1997;2336-2344.
39. Preece N.E., Gadian D.G., Houseman J., Williams S.R. Lithium-induced modulation of cerebral inositol phosphate metabolism in the rat: a multinuclear magnetic resonance study in vivo. Lithium. 3:1992;287-297.
40. 31P-NMR spectra of cats receiving lithium chloride systemically. Biol. Psychiatry. 21:1986;694-698.
41. Sherman W.R., Munsell L.Y., Gish B.G., Honchar M.P. Effects of systematically administered lithium on phosphoinositide metabolism in rat brain, kidney and testis. J. Neurochem. 44:1985;798-807.
42. Sherman W.R., Leavitt A.L., Honchar M.P., Hallcher L.M., Phillips B.E. Evidence that lithium alters phosphoinositide metabolism: chronic administration elevates primarily D-myoinositol-1-phosphate in cerebral cortex of the rat. J. Neurochem. 36:1981;1947-1951.
43. 31P MRS. Biol. Psychiatry. 46:1999;1634-1641.
44. 31P MRS. Biol. Psychiarty. 40:1996;235-246.
45. Stoll A.L., Severus W.E. Mood stabilizers: shared mechanisms of action at postsynaptic signal-transduction and kindling processes. Harvard Rev. Psychiatry. 4:1996;77-89.
46. Sun G.Y., Navidi M., Yoa F.G., Lin T.N., Orth O.E., Stubbs E.B. Jr., MacQuarrie R.A. Lithium effects on inositol phospholipids and inositol phosphates: evaluation of an in vivo model for assessing polyphosphoinositide turnover in brain. J. Neurochem. 58:1992;290-297.
47. Vadnal R., Parthasarathy R. Myoinositol monophosphatase: diverse effects of lithium, carbamazepine, and valproate. Neuropsychopharmacology. 12:1995;277-285.
48. Watson D.G., Lenox R.H. Chronic lithium-induced downregulation of MARCKS in immortalized hippocampal cells: potentiation by muscarinic receptor activation. J. Neurochem. 67:1996;767-777.
49. Watson D.G., Watterson J.M., Lenox R.H. Sodium valproate downregulates the myristoylated alanine-rich C kinase substrate (MARCKS) in immortalized hippocampal cells: a property of protein kinase C-mediated mood stabilizers. J. Pharmacol. Exp. Ther. 285:1998;307-316.
50. Yuan P.X., Chen G., Huang L.D., Manji H.K. Lithium stimulates gene expression through the AP-1 transcription factor pathway. Mol. Brain. Res. 58:1998;225-230.
51. 1HMR spectroscopy of children with bipolar disorder. Int. Soc. Magn. Res. Med. 7th Annual meeting, Philadelphia, PA:1999;. Abstract 1471.